We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 588.00 | 5.18% | 11,940.00 | 11,934.00 | 11,940.00 | 12,086.00 | 11,850.00 | 11,890.00 | 917,653 | 10:45:09 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.06 | 184.94B |
From Apr 2022 to Apr 2024
By Denny Jacob
International stocks trading in New York closed higher on Friday.
The S&P/BNY Mellon index of American depositary receipts edged up 0.9% to 154.22. The European index gained 0.7% to 146.92. The Asian index climbed 1.3% to 183.36. The Latin American index edged down 0.1% to 194.98, while the emerging-markets index moved up 1.2% to 308.66.
Alibaba Group Holding Ltd. was among those whose ADRs traded actively.
The Chinese e-commerce company rose 3.4% after Chinese authorities recently acquired a stake in its subsidiary.
AstraZeneca PLC rose 1.4% after the pharmaceutical company said tezspire received a positive opinion from the European Medicine Agency's Committee for Medicinal Products for Human Use for self-administration in a pre-filled, single-use pen for patients ages 12 and up with severe asthma.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
January 13, 2023 16:48 ET (21:48 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
